Advertisement
Research Article| Volume 20, ISSUE 11, P1174-1188, November 1985

Obsessive-compulsive disorder and serotonin: Is there a connection?

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Reports of the antiobsessional efficacy of clomipramine have led to a “serotonin hypothesis” of obsessive-compulsive disorder (OCD). To test this hypothesis, 16 outpatients with DSM-III OCD were studied using several measures of serotonergic function. Platelet 3H-imipramine binding and serotonin uptake were not significantly different between the OCD patients and a normal, age-matched control group. The level of the metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) was significantly higher in a small cohort of obsessionals compared with healthy volunteers, possibly reflecting increased brain serotonin turnover. In a direct test of the role of serotonin uptake in clomipramine's antiobsessional effects, the serotonin uptake inhibitor zimelidine was compared with the noradrenergic uptake inhibitor desipramine in a double-blind, controlled study. Zimelidine reduced CSF 5-HIAA, but was clinically ineffective in this group. Desipramine had weak but significant clinical effects. Nonresponders to zimelidine or desipramine improved significantly during a subsequent double blind trial of clomipramine. These findings demonstrate that pharmacological blockade of serotonin reuptake alone is not sufficient for an antiobsessional response.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ananth J.
        • Pecknold J.C.
        • Van der Steen N.
        Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis.
        Prog Neuropsychopharmacol. 1981; 5: 257-262
        • Asarch K.B.
        • Shih J.C.
        • Kulescar A.
        Decreased 3H-imipramine binding in depressed males and females.
        Commun Psychopharmacol. 1980; 4: 425-429
        • Asberg M.
        • Traskman L.
        • Thoren P.
        5-HIAA in the CSF: A biochemical suicide predictor?.
        Arch Gen Psychiatry. 1976; 33: 1196-1200
        • Asberg M.
        • Thoren P.
        • Bertilsson L.
        Clomipramine treatment of obsessive disorder—biochemical and clinical aspects.
        Psychopharmacol Bull. 1982; 18: 13-21
        • Asberg M.
        • Bertilsson L.
        • Martensson B.
        • Scalia-Tomba G.P.
        • Thoren P.
        • Traskman-Bendz L.
        CSF monoamine metabolites in melancholia.
        Acta Psychiatr Scand. 1984; 69: 201-219
        • Bertilsson L.
        • Asberg M.
        Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: Methodological aspects.
        in: Usdin E. Asberg M. Bertilsson L. Sjoqvist F. Frontiers in Biochemical and Pharmacological Research in Depression. Raven Press, New York1984: 27-35
        • Brown G.L.
        • Goodwin F.K.
        • Ballenger J.C.
        • Goyer P.F.
        • Major L.F.
        Aggression in humans correlates with cerebrospinal fluid amine metabolites.
        Psychiatry Res. 1979; 1: 131-139
        • Fernstrom S.
        • Wurtman R.J.
        Nutrition and the brain.
        Sci Am. 1974; 230: 84-96
        • Fuxe K.
        • Ogren S.O.
        • Agnati L.F.
        • Benfenati F.
        • Fredholm B.
        • Anderson K.
        • Zini I.
        • Eneroth P.
        Chronic antidepressant treatment and central 5-HT synapses.
        Neuropharmacology. 1983; 22: 389-400
        • Hall H.
        • Ross R.
        • Ogren S.O.
        • Galwell L.
        Binding of a specific 5 HT uptake inhibitor, 3H-norzimelidine to rat brain homogenates.
        Eur J Pharmacol. 1982; 80: 281-282
        • Hamilton M.
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1967; 6: 278-296
        • Insel T.R.
        • Murphy D.L.
        The psychopharmacologic treatment of obsessive compulsive disorder: A review.
        J Clin Psychopharmacol. 1981; 1: 304-311
        • Insel T.R.
        • Murphy D.L.
        • Cohen R.M.
        • Alterman I.
        • Kilts C.
        • Linnoila M.
        Obsessive compulsive disorder: A double blind trial of clomipramine and clorgyline.
        Arch Gen Psychiatry. 1983; 40: 605-612
        • Jimerson D.C.
        • Berrettini W.
        Cerebrospinal fluid amine metabolite studies in depression: Research update.
        in: Beckmann H. Riederer P. Pathochemical Markers of the Psychoses. Springer Verlag, Berlin1985: 129-143
        • Kahn R.S.
        • Westenberg H.G.M.
        • Jolles J.
        Zimelidine treatment of obsessive-compulsive disorder.
        Acta Psychiatr Scand. 1984; 69: 259-261
        • Lingjaerde O.
        Inhibitory effects of clomipramine and related drugs on serotonin uptake in platelets: More complicated than previously thought.
        Psychopharmacology (Berlin). 1979; 61: 245-249
        • Lingjaerde O.
        Platelet serotonin uptake inhibition as a basis for monitoring antidepressant drug treatment.
        J Clin Psychopharmacol. 1984; 4: 76-81
        • Linnoila M.
        • Insel T.
        • Kilts C.
        • Potter W.Z.
        • Murphy D.L.
        Plasma steady-state concentrations of hydroxylated metabolites of clomipramine.
        Clin Pharmacol Ther. 1982; 32: 208-211
        • Linnoila M.
        • Virkkunen M.
        • Scheinin M.
        • Nuutila A.
        • Rimon R.
        • Goodwin F.K.
        Low cerebrospinal fluid 5-HIAA concentration differentiates impulsive from non-impulsive violent behavior.
        Life Sci. 1983; 33: 2609-2614
        • Lowry O.M.
        • Rosebrough N.
        • Farr L.A.
        • Randall R.J.
        Protein measurement with the Folin phenol reagent.
        J Biol Chem. 1951; 193: 165-272
        • Meltzer H.H.
        • Arora R.C.
        • Song P.
        Serotonin uptake in blood platelets as a biological marker for major depressive disorder.
        in: Usdin E. Costa E. Biological Markers in Psychiatry and Neurology. Pergamon Press, New York1982: 39-48
        • Ogren S.O.
        • Ross S.B.
        • Hall H.
        • Fuxe K.
        The pharmacology of zimelindine: A 5 HT selective reuptake inhibitor.
        Acta Psychiatr Scand (Suppl). 1981; 63: 127-151
        • Paul S.M.
        • Rehavi M.
        • Hulihan B.
        • Skolnick P.
        • Goodwin F.K.
        A rapid and sensitive radioreceptor assay for tertiary amine tricyclic antidepressants.
        Commun Psychopharmacol. 1980; 4: 487-494
        • Paul S.M.
        • Rehavi M.
        • Rice K.
        • Ittah Y.
        • Skolnick P.
        Does high affinity [3H]-imipramine binding label serotonin reuptake sites in brain and platelets?.
        Life Sci. 1981; 28: 2753-2760
        • Paul S.M.
        • Rehavi M.
        • Skolnick P.
        • Ballenger J.C.
        • Goodwin F.K.
        Depressed patients have decreased binding of 3H-imipramine to the platelet serotonin “transporter”.
        Arch Gen Psychiatry. 1981; 38: 1315-1319
        • Pawlowski L.
        • Ruczynska J.
        • Maj J.
        Zimelidine and clomipramine: Different influence on fenfluramine but not p-chloroamphetamine-induced pharmacological effects.
        Neurosci Lett. 1980; 16: 203-207
        • Post R.M.
        • Ballenger J.C.
        • Goodwin F.K.
        Cerebrospinal fluid studies of neurotransmitter function in manic and depressive illness.
        in: Wood J.H. Neurobiology of Cerebrospinal Fluid. Plenum Press, New York1980: 685-695
        • Potter W.Z.
        • Calil H.M.
        • Extein I.
        • Goodwin F.K.
        Specific norepinephrine and serotonin uptake inhibitors in man: A crossover study with pharmacokinetic, biochemical, neuroendocrime, and behavioral parameters.
        Acta Psychiatr Scand (Suppl). 1981; 63: 152-165
        • Prasad A.
        A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis.
        Pharmacopsychiatria. 1984; 17: 61-62
        • Raisman R.
        • Sechter D.
        • Briley M.S.
        • Zarifian E.
        • Langer S.Z.
        High affinity 3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers.
        Psychopharmacology (Berlin). 1981; 75: 368-371
        • Rasmussen S.
        Lithium and tryptophan augmentation in clomipramine-resistant obsessive compulsive disorder.
        Am J Psychiatry. 1984; 141: 1283-1285
        • Rehavi M.
        • Weizman R.
        • Carel C.
        • Apter A.
        • Tyano S.
        High affinity 3H imipramine binding in platelets of children and adolescents with major affective disorders.
        Psychiatry Res. 1984; 13: 31-39
        • Ross S.B.
        • Renyi A.L.
        Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z) and (E)-3-(4-bromophenyl)-N, N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues.
        Neuropharmacology. 1977; 16: 57-63
        • Ross S.B.
        • Aperia B.
        • Beck-Friis J.
        • Jansa S.
        • Wetterberg L.
        • Aberg A.
        Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo.
        Psychopharmacology (Berlin). 1980; 67: 1-7
        • Saavedra J.
        • Axelrod J.
        Brain tryptamine and the effect of drugs.
        Adv Biochem Psychopharmacol. 1974; 10: 135-139
        • Scheinin M.
        • Chang W.H.
        • Jimerson D.C.
        • Linnoila M.
        Simultaneous determinations of MHPG, 5-HIAA, and HVA in CSF with HPLC using electrochemical detection.
        Anal Biochem. 1983; 131: 246-253
        • Stern R.S.
        • Marks I.M.
        • Mawson D.
        Clomipramine and exposure for compulsive rituals: Plasma levels, side effects, and outcome.
        Br J Psychiatry. 1980; 136: 161-166
        • Thoren P.
        • Asberg M.
        • Bertilsson L.
        • Traskman L.
        Clomipramine treatment of obsessive compulsive disorder: II. Biochemical aspects.
        Arch Gen Psychiatry. 1980; 37: 1289-1295
        • Thoren P.
        • Asberg M.
        • Cronholm B.
        • Jornestedt L.
        • Traskman L.
        Clomipramine treatment of obsessive compulsive disorder: A controlled clinical trial.
        Arch Gen Psychiatry. 1980; 37: 1281-1289
        • Traskman L.
        • Asberg M.
        • Bertilsson L.
        Plasma levels of chlorimipramine and its desmethyl metabolite during treatment of depression.
        Clin Pharmacol Ther. 1979; 26: 600-609
        • Traskman L.
        • Asberg M.
        • Bertilsson L.
        • Sjostrand L.
        Monoamine metabolites in CSF and suicidal behavior.
        Arch Gen Psychiatry. 1981; 38: 631-636
        • Vandel B.
        • Vandel S.
        • Jounet J.M.
        Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.
        Eur J Clin Pharmacol. 1982; 22: 15-20
        • Van Praag H.M.
        CSF 5-HIAA and suicide in non-depressed schizophrenics.
        Lancet. 1983; ii: 977-978
        • Whitaker P.M.
        • Warsh J.J.
        • Stancer H.C.
        • Persad E.
        • Vint C.K.
        Seasonal variation in platelet 3H-imipramine binding: Comparable values in control and depressed populations.
        Psychiatry Res. 1984; 11: 127-131
        • Yaryura-Tobias J.S.
        • Bhagavan H.N.
        l-Tryptophan in obsessive compulsive disorders.
        Am J Psychiatry. 1977; 134: 1298-1299
        • Zilberstein D.
        • Dwyer D.M.
        Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania.
        Science. 1984; 226: 977-979